Temelimab for Multiple Sclerosis Explained by Neurologist
Vložit
- čas přidán 26. 09. 2023
- Temelimab (GNbAC1) is a drug being developed for multiple sclerosis which targets the envelope protein of human endogenous retrovirus W.
Please watch this video for a background on why people believe HERV-W may be part of the cause of MS: • Does HERV-W Cause Mult...
This video reviews human endogenous retroviruses, temelimab, and the results from 3 clinical trials.
Selected Sources:
Presentation on Temelimab by GenNeuro: geneuro.com/data/documents/GN... phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients: pubmed.ncbi.nlm.nih.gov/25392...
The Envelope Protein of a Human Endogenous Retrovirus-W Family Activates Innate Immunity through CD14/TLR4 and Promotes Th1-Like Responses: journals.aai.org/jimmunol/art...
Update on CHANGE-MS: Clinical Trial Results for GNbAC1: practicalneurology.com/articl...
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study: pubmed.ncbi.nlm.nih.gov/34240...
Comment or ask questions below! I would be happy to answer!
Subscribe on CZcams for more videos every Wednesday!
Make video requests in the comments section!
Check out my book “Resilience in the Face of Multiple Sclerosis” FREE on Amazon: amazon.com/dp/B07WP7H5LK It's about 5 people with MS who live incredible lives, the science and psychology of resilience, mindfulness, and ho’oponopono. Paperback priced to generate $0 royalty.
Dr. Brandon Beaber is a board-certified neurologist with subspecialty training in multiple sclerosis and other immunological diseases of the nervous system. He is a partner in the Southern California Permanente Medical Group and practices in Downey, California (South Los Angeles). He has several publications on MS epidemiology and has participated in clinical trials for MS therapeutics. You can follow him on twitter @Brandon_Beaber where he regularly posts about MS news and research.
Follow me on twitter: / brandon_beaber
Music: INNER GRACE - Copyright 2018 Wilton Vought Source: Really Really Free Music Link: • Video T
he video material by Dr. Brandon Beaber is general educational material on health conditions and is not intended to be used by viewers to diagnose or treat any individual's medical condition. Specifically, this material is not a substitute for individualized diagnostic and treatment advice by a qualified medical/health practitioner, licensed in your jurisdiction, who has access to the relevant information available from diagnostic testing, medical interviews, and a physical examination. To the extent that Dr. Beaber endorses any lifestyle change, behavioral intervention, or supplements, the viewer should consult with a qualified healthcare professional to determine the safety and efficacy of the intervention in light of their individualized information.
Thanks Dr. Beaber for continuing this topic from last week. I would like to see this study continue and see where it goes. I see this as an adjunct to a DMT. As we now know that MS is more than DMT's, MRI's and lesions, we need more study and trials on meds that can tackle smouldering MS and PIRA. Pharma companies love money, so they need convincing that this is a whole new market for them to cash in on lol. I'm an "old" at 56 so I'm basically cut out of clinical trials, but if not for that, I would gladly participate! Thanks again!
DMT, remylination drug and a smouldering stopper to make ms "boring"
Thank you.
Something to watch on my periphery for this edss 3.5. ppms-post hsct 59 yr. old patient as I focus on positive happiness andan active household fitness recovery.
Thanks Dr. Beaber. So interesting. We have seen so much about smoldering MS and PIRA lately and it is nice to see clinical trials on drugs that may help.
Thank you for this interesting perspective. I confirm that GeNeuro indeed seeks to develop temelimab in combination with existing anti-inflammatory drugs to specifically target neurodegeneration. The challenges you describe are acurate, and we do not make the rules either ;-), but the need is such that we are determined to go forward.
Very interesting studies. Don't know what to believe anymore-just when we thought EBV was the culprit. Thanks for the overview
Thank you Dr. Beaber for the follow-up video. Reading the onvideo stats and listening to your descriptions and commentary I feel Temelimab would most probably become a supplementary medicine to DMTs for MS, especially for progressive versions. However I also feel that more studies should be made over the cross-reaction of Temelimab with each available DMT and how safe the combination would be for us (eg Temelimab + Tysabri, Temelimab + Ocrevus etc).
Dear Dr. Brandon, I'm a young guy from Italy (27 yo)... I'm currently receiving 54mg/kg Temelimab because of Long Covid syndrome.
How interesting! Thank you for breaking this down!
Very interesting.
Great video! Thanks! Does Temelimab work against other HERVS as HERVK?Or it is specific for only HERV-W?
great video doc , i see that there is a lot of trials now targeting mainly progressive ms, do you think that now there is more of a focus on stopping PIRA rather than remyelination ? do you think stopping progression would be enough for the brain to repair itself without the need of remyelinating drugs?
Are there any drugs that are used off label for MS to slow the progression besides the current DMT?
Please help me! I was diagnosed with MS a few months ago. I’ve had several relapses since then.
Very interesting. SO many NEW trials throughout the medical field with these new meds. Thank you for keeping us updated on how they are faring.